US imposes 100% tariff on imported patented pharmaceuticals with exemptions and caveats

Consensus Summary

Donald Trump imposed a 100 percent tariff on patented pharmaceuticals manufactured outside the US, excluding generic drugs, under Section 232 of the Trade Expansion Act. The move aims to reshoring production and address national security concerns, despite the US Supreme Court invalidating Trump’s broader 'Liberation Day' tariffs in February. Australia, which exported around $1.9 billion in pharmaceuticals to the US in 2024, faces potential economic disruption, particularly for CSL, the country’s largest biotech firm. CSL, which has significant US manufacturing capacity and is expanding its Illinois facility with a $1.5 billion investment, is expected to qualify for exemptions or reduced tariffs due to its domestic production. The US has granted lower tariff rates (10-15 percent) to countries like Japan, the EU, and the UK, while Australia, lacking a negotiated deal with the Trump administration, faces the full 100 percent rate. The tariff introduces incentives for companies to relocate production to the US, with tariffs dropping to 20 percent for those who do so and potentially zero if the US achieves 'most favoured nation' drug pricing status. The Australian government, led by Health Minister Mark Butler, has firmly rejected US pressure to alter the country’s Pharmaceutical Benefits Scheme, which ensures affordable drug prices for Australians. Both major political parties have expressed concern over the tariff’s impact on Australian exporters, with the opposition pledging to work with the government to secure exemptions. The US administration argues that the tariff is necessary to secure a domestic supply of critical medicines, while critics warn it could increase costs for American consumers and disrupt global pharmaceutical supply chains.